Icon Plc · NASDAQ:ICLR
Icon — Investor Day (March 2007)
123 slides from Icon's investor day presentation, Mar 2, 2007
Slide 1: ICON plc Global Organization
Chairman Dr. John Climax ICON Corporate Dev President Bill Taaffe CEO Peter Gray CFO Ciaran Murray ICON Development Solutions President Dr Thomas Frey ICON Central Laboratories President Bob Scott-Edwards ICON Contracting Solutions Tony Southers Snr VP VP Corporate QA Jo Coyle VP Global IT Mike McGr
Slide 2: ICON PLC Investor Relations Day 2007
ICON PLC Investor Relations Day 2007 Peter Gray March 2 nd 2007
Slide 3: ICON plc Global Organization
Chairman Dr. John Climax Dev ICON Corporate President Bill Taaffe CEO Peter Gray CFO Ciaran Murray ICON Development Solutions President Dr Thomas Frey ICON Central Laboratories President Bob Scott-Edwards ICON Contracting Solutions Tony Southers Snr VP VP Corporate QA Jo Coyle VP Global IT Mike McGr
Slide 4: Forward Looking Statements
Forward Looking Statements Certain statements contained herein including, without limitation, statements containing the words “believes,” “anticipates,” “intends,” “expects” and words of similar import, constitute forward-looking statements concerning the Company's operations, performance, financial
Slide 5: The Journey So Far
The Journey So Far
Slide 6: The Journey So Far
The Journey So Far
Slide 7: The Journey So Far
The Journey So Far
Slide 8: The Journey So Far
The Journey So Far
Slide 9: The Journey So Far
The Journey So Far
Slide 10: The Journey So Far
The Journey So Far
Slide 11: The Journey So Far
The Journey So Far
Slide 12: The Journey So Far
The Journey So Far
Slide 13: The Journey So Far
The Journey So Far
Slide 14: The Journey So Far
The Journey So Far
Slide 15: The Journey So Far
The Journey So Far
Slide 16: Symbol of Excellence
‘Symbol ot Excelence
Slide 17: The Journey So Far
2006 • Revenues $450 million • Operating Profits $47m • EPS $1.33 • Staff 4,300 1990 • Revenues $0.5 million • Operating Profits $0m • Staff The Journey So Far 2007 Guidance • Revenues $530-$550 • Operating Profits $58 - $62m • EPS $1.63 - $1.71 • Staff 4,800 – 5,100
Slide 18: Market Environment
Market Environment
Slide 19: Strong Market Environment with...
*Source: Tufts Centre for Study of Drug Development Strong Market Environment with... • Fundamental R&D Spending Growth Trend 6%- 8% p.a. ¯ Phase II / III pipelines strengthening • Increased Outsourcing ¯ Being accelerated by activity & funding in Biotech / Speciality ¯ Globalisation of clinical res
Slide 20: Biotech fund raising
Biotech fund raising ($billions) Source: Burrill and Company …US Biotech Funding continuing to grow, leading to...
Slide 21: Growth in companies with active clinical projects
Source: Informa Health …significant growth in the number of companies with active clinical projects,…. Number of companies running clinical projects
Slide 22: Growth in original IND applications
Source: FDA Centre for Drug Evaluation & Research (1) Includes active INDs for Therapeutic Biological Products Transferred from CBER to CDER effective 10/01/2003 (2) Includes INDs for Therapeutic Biological Products Transferred from CBER to CDER … good recent growth in original IND Applications,….
Slide 23: Growth in number of active INDs
Source: FDA Number of Active INDs … which has lead to significant growth in the number of active INDs,… 49% Increase since 2000
Slide 24: Enriching pipelines
Source: IMS R&D Focus, Dec 2006 and previous year SMRs 2002 – 2006 46% Growth Phase I – II …which is enriching pipelines generally, and leading to…
Slide 25: Re-emergence of growth in NDA applications
1) Includes the Therapeutic Biological Products Transferred from CBER to CDER effective 10/01/2003 Source: FDA Centre for Drug Evaluation & Research ….a re-emergence of growth in NDA applications.
Slide 26: Not a Pig in a Python
Not a “ Pig in a Python”, rather a …….
Slide 27: Pre-Clinical to Phase-IV
Pre-Clinical Phase-I Phase-ll Phase-lill Phase-IV a
Slide 28: Pre-Clinical to Phase-IV
Pre-Clinical Phase-I Phase-ll Phase-lill Phase-IV —— /
Slide 29: Pre-Clinical to Phase-IV
Pre-Clinical Phase-I Phase-ll Phase-lill Phase-IV
Slide 30: Gross Business Wins
ICON Gross Business Wins - Last 10 Quarters ($ millions) Strong business wins have led to…..
Slide 31: Net Business Wins and Book to Bill Ratio
Net Business Wins Book to Bill Ratio …good Net New Business Wins and strong book-to-bill…
Slide 32: Record total backlog levels
…leading to record total backlog levels… ($ millions)
Slide 33: Backlog coverage of next 4 quarters revenues
Value of backlog forecast to be earned in next 4 quarters % coverage of next 4 quarters forecast revenues …, strong forecast coverage of next 4 quarters revenues……..
Slide 34: Client Concentration 2006 v 2005
Client Concentration 2006 v 2005 …..and a broadening of the customer base.
Slide 35: Strategy
STRATEGY
Slide 36: Core Strategy is Organic Growth
2006 • Revenues $450 million • Operating Profits $51m • Bookings $665m • Staff 4,300 Core Strategy is Organic Growth, with acquisitions adding new services or scale.
Slide 37: Core Strategy is Organic Growth
Core Strategy is Organic Growth, with acquisitions adding new services or scale.
Slide 38: Core Strategy is Organic Growth
Core Strategy is Organic Growth, with acquisitions adding new services or scale.
Slide 39: Core Strategy is Organic Growth
Core Strategy is Organic Growth, with acquisitions adding new services or scale.
Slide 40: Core Strategy is Organic Growth
Core Strategy is Organic Growth, with acquisitions adding new services or scale.
Slide 41: Core Strategy is Organic Growth
Core Strategy is Organic Growth, with acquisitions adding new services or scale.
Slide 42: Core Strategy is Organic Growth
Core Strategy is Organic Growth, with acquisitions adding new services or scale.
Slide 43: Core Strategy is Organic Growth
Core Strategy is Organic Growth, with acquisitions adding new services or scale.
Slide 44: Core Strategy is Organic Growth
Core Strategy is Organic Growth, with acquisitions adding new services or scale.
Slide 45: Core Strategy is Organic Growth
Core Strategy is Organic Growth, with acquisitions adding new services or scale.
Slide 46: Core Strategy is Organic Growth
Core Strategy is Organic Growth, with acquisitions adding new services or scale.
Slide 47: Goal 2010
Goal 2010 • Revenues $1bn • Of which acquisitions contribute $150m • Margins ≥ 14% Core Strategy is Organic Growth, with acquisitions adding new services or scale.
Slide 48: ICON plc Global Organization
Chairman Dr. John Climax ICON Corporate Dev President Bill Taaffe CEO Peter Gray CFO Ciaran Murray ICON Development Solutions President Dr Thomas Frey Beacon Bioscience CEO Ted Gastineau ICON Central Laboratories President Bo Scott-Edwards b ICON Contracting Solutions Tony Southers Snr VP VP Corpora
Slide 49: Financial Performance
Financial Performance
Slide 50: Recent Financial Performance (Q4)
Recent Financial Performance ($ millions, except EPS) Q4 ’06 Q4 ’PY % Increase Net Revenue 128.9 88.1 46.4% Direct Costs 72.5 48.7 48.8% SG & A 37.6 26.8 40.3% D & A 3.9 3.5 11.2% _____ _____ _____ Operating Income 14.9 65% Net Income 12.4 79% _____ _____ _____ EPS (ex SFAS123R) 42c 24c 75% EPS (Inc
Slide 51: Recent Financial Performance (FY)
Recent Financial Performance ($ millions, except EPS) FY 2006 FY 2005 % Increase Net Revenue 342.8 32.9% Direct Costs 189.6 34% SG & A 134.7 108.5 24.1% D & A 14.9 13.9 7.4% _____ _____ _____ Operating Income 51.9 30.8 68.6% Net Income 42.4 24.3 74.3% _____ _____ _____ EPS (ex SFAS123R) 145c 86c 68.
Slide 52: Net Revenue CAGR of 29%
Net Revenue CAGR of 29% over 7 Years
Slide 53: Revenue FY2001 to FY2007
Fy2001 FY2002 FY2003 FY2004 FY2005 FY2006 ~~ FY2007
Slide 54: Summary Balance Sheet and Cash Flow
May 31, (Year) Dec 31, 05 (7 mths) Dec 31, (Year) Net Cash $78.4 $82.3 $98 Total assets $347.6 $349.1 $476.3 Shareholder’s equity $233.1 $241.6 $302.7 Cashflow from operations $23.8 $11.7 $51.5 Capital expenditures $15.6 $7.8 $12.3 Shares outstanding 27.8 28.0 28.5 Summary Balance Sheet and Cash Flo
Slide 55: Revenue Growth v Peers
* Source SEC Filings Revenue Growth v Peers: Net Revenue CAGR between 2000 and 2005
Slide 56: Investment Highlights
Investment Highlights • Top 4 global CRO • Strong market fundamentals • Outstanding record of organic growth • Strong balance sheet • Margin expansion opportunity • Good strategic position
Slide 57: ICON plc Global Organization
Chairman Dr. John Climax ICON Corporate Dev President Bill Taaffe CEO Peter Gray ICON Development Solutions President Dr Thomas Frey Beacon Bioscience CEO Ted Gastineau ICON Central Laboratories President Bob Scott-Edwards ICON Contracting Solutions Tony Southers Snr VP VP Corporate QA Jo Coyle VP G
Slide 58: ICON Clinical Research Service Overview
ICON Clinical Research Service Overview
Slide 59: Services
Services • ICON Clinical Research is a global provider of outsourced Phase II – IV development services to the pharmaceutical, biotechnology and medical device industries. • Clinical trial management services include: ¯ Project Management ¯ Clinical Monitoring ¯ Data Management ¯ Biostatistics ¯ Med
Slide 60: ICON's Business Trends In Clinical Research
ICON’s Business Trends In Clinical Research
Slide 61: Global RFP Flow
1 Excludes IVR only data 2 Gross = All RFPs Received 3 Net = (Gross minus Cancelled, Declined, Non Award, Sent to Other Division) Clinical Research 2003 – 2006 Annual (Gross vs. Net) Global RFP Flow
Slide 62: Global RFP Value by Participating Region
1 Excludes IVR and Lab data 2 Gross = All RFPs Received 3 Net = (Gross minus Cancelled, Declined, Non Award, Sent to Other Division) Clinical Research 2003 - 2006 Annual (Gross vs. Net) Global RFP Value ($ Million) by Participating Region
Slide 63: Global Historical Awards by Originating Region
1 Excludes Change Order Values 1 Includes IVR Values 2 Based on Award Notification Date 3 Adjusted Value not used as 2003-2005 data would not be accurate Award Value in Millions Global Historical Awards by Originating Region
Slide 64: Global Historical Awards by Participating Region
1 Excludes Change Order Values 1 Includes IVR Values 2 Based on Award Notification Date 3 Adjusted Value not used as 2003-2005 data would not be accurate Award Value in Millions Global Historical Awards by Participating Region
Slide 65: Award Values by Therapeutic Area Summary
Award Value in Millions Excludes IVR Values Award Values by Therapeutic Area Summary Award Value in Millions
Slide 66: Global/Regional Award Values 2006
Excludes IVR Values Award Value in Millions Global/Regional Award Values Therapeutic Area Summary - 2006
Slide 67: Therapeutic Growth (Awards)
+ 200% Therapeutic Growth (Awards) Significant growth in Oncology, CNS, Anti-infectives & Endocrinology
Slide 68: Therapeutic Growth (% Revenues)
2003 2006 Therapeutic Growth (%Revenues)
Slide 69: Composition of Business
Composition of Business (Phase II-IV only) (% of Revenue)
Slide 70: Increased Outsourcing of Full Service Work
Increased Outsourcing of Full Service Work (U.S. Business)
Slide 71: Total Number of Active Projects by Region
Total Number of Active Projects by Region
Slide 72: Increasing Contribution by EU and ROW
Increasing Contribution by EU and ROW to ICON’s Business growth….
Slide 73: Active Projects & Therapeutic Mix by Region
Active Projects & Therapeutic Mix by Region (% of Backlog for 2007)
Slide 74: Concluding Remarks
Concluding Remarks
Slide 75: ICON is well Positioned to...
ICON is well Positioned to……. • Capitalise on the expanding market in late phase and safety studies • Increase geographical “foot print” to enhance patient recruitment for global studies • Shift backend support to low cost regions such as India • Utilize technology to improve efficiency and enhance
Slide 76: ICON plc Global Organization
Chairman Dr. John Climax ICON Corporate Dev President Bill Taaffe CEO Peter Gray CFO Ciaran Murray ICON Development Solutions President Dr Thomas Frey Beacon Bioscience CEO Ted Gastineau ICON Central Laboratories President Bob Scott-Edwards ICON Contracting Solutions Tony Southers Snr VP VP Corporat
Slide 77: EDC - Origins of the species
• Electronic Data Capture (EDC) has been around almost years • Adoption has been slower than the technologists predicted • So what’s changed EDC – Origins of the species
Slide 78: Evaluation and selection of EDC vendors
ICON’s evaluation and selection of vendors • Historical experience with 14 different systems ¯ Driven by state of the market and client variation (no clear leader) ¯ Breath of experience beyond the reach of Pharma • Evaluated top 15 systems during 2004 ¯ Functionality (Investigator, Monitor & Data M
Slide 79: Adoption metrics
Adoption metrics • In the last 3 years ¯ ICON has won 6 times as many EDC projects than in the preceding years ¯ EDC Wins have more than doubled year on year • wins in 2004, 17 wins in 2005 and 38 wins in 2006 ¯ Requests for proposals featuring EDC comprised about 35% of our portfolio at the end of
Slide 80: Drivers for adoption - cost, speed & visibility
Supports complex studies (eg Oncology) Faster time to database lock and final study reports Access to data (Adaptive trials) >$6M Drivers for adoption – cost, speed & visibility
Slide 81: Short Break
ICON Investor Relations Day 2007 Short Break
Slide 82: ICON plc Global Organization
Chairman Dr. John Climax ICON Corporate Dev President Bill Taaffe CEO Peter Gray CFO Ciaran Murray ICON Development Solutions President Dr Thomas Frey Beacon Bioscience CEO Ted Gastineau ICON Central Laboratories President Bo Scott-Edwards b ICON Contracting Solutions Tony Southers Snr VP VP Corpora
Slide 83: IMPROVE
IMPROVE • Root and branch review of Standard Operating Procedures to enhance consistency of client experience and efficiency of operational delivery ¯ Data Management ¯ Site visits ¯ Document Management & Archiving ¯ Regulatory & Ethics submissions ¯ Site selection & feasibility
Slide 84: EXPEDITE
EXPEDITE • A review of project management methodology, procedures, and tools, to enhance consistency of client experience and effectiveness of operational delivery ¯ Consistent work break down structure across systems ¯ Templates to assist in task planning ¯ More structured approach to risk manageme
Slide 85: New Investments in tools
New Investments in tools • Continuous investment in new tools to support new processes and to provide a scaleable system framework for the enterprise ¯ Clinical Trial management system ( ICOTrial ) active on over 70 projects ¯ SOPs management systems launched at the end of 2006 (iDoc ) ¯ Sales conta
Slide 86: Supporting Growth - Systems, Process, and QA
Supporting Growth – Systems, Process, and QA
Slide 87: ICON plc Global Organization
Chairman Dr. John Climax ICON Corporate Dev President Bill Taaffe CEO Peter Gray CFO Ciaran Murray ICON Development Solutions President Dr Thomas Frey Beacon Bioscience CEO Ted Gastineau ICON Central Laboratories President Bob Scott-Edwards ICON Contracting Solutions Tony Southers Snr VP VP Corporat
Slide 88: Total R&D Spend of Japanese Pharmaceutical Companies
JPMA – Japan Dec 2006 Total R&D Spend of Japanese Pharmaceutical Companies
Slide 89: The Revenue of CROs in Japan
JCROA-Japan, Dec 2006 The Revenue of CROs in Japan
Slide 90: CROs in Japan
Clinical Staff Location ICON Tokyo Quintiles offices in Japan CMIC offices in Japan EPS offices in Japan MSP 3-4 offices in Japan Parexel Kobe/Tokyo CROs in Japan (as of 2006)
Slide 91: CRO Opportunities in Japan
CRO Opportunities in Japan • Domestic growth ¯ Increasing Demands • Headcount cut in pharma Vs more clinical trials • Pivotal studies Vs local studies • Mega companies (big three) Vs middle/small pharmas • CRO growth Vs SMO involvement (less SMO needs) • SMO currently acts as a ‘patient broker’ • Re
Slide 92: Clinical Research in India - Medium term opportunity
Clinical Research in India – Medium term opportunity • Progressively developing infrastructure ( >14000 hospitals by 2010) • Cost effectiveness -50% of the cost in US • Large Population ¯ Genetically heterogeneous ¯ Treatment Naive Patient population ¯ Expedited target recruitment • Indications ¯ Pr
Slide 93: Geographical spread of current ICON managed sites
Amritsar Geographical spread of current ICON managed sites
Slide 94: Clinical Research in China - Longer term opportunity
Clinical Research in China – Longer term opportunity • Top investigators-5-10 years global experience • Patient pool/ Recruitment reliability (216 hospitals,53 different specialties for GCP certified clinical trials centers) • Rapidly expanding pharmaceutical market ---5 th largest by 2010, 2 nd /3
Slide 95: ICON plc Global Organization
Chairman Dr. John Climax ICON Corporate Dev President Bill Taaffe CEO Peter Gray CFO Ciaran Murray ICON Developme nt Solutions President Dr Thomas Frey Beacon Bioscience CEO Ted Gastineau ICON Central Laboratories President Bob Scott-Edwards ICON Contracting Solutions Tony Southers Snr VP VP Corpora
Slide 96: ICON Development Solutions
ICON Development Solutions • Medeval: Full Service Clinical Pharmacology Unit, Manchester, UK • GloboMax: Strategic Product Development Consulting, Baltimore, US • ICON Consulting (YRCR): Regulatory Affairs Consulting, Early Phase Clinical Operations, Marlow, UK
Slide 97: Excellence in Project Management
0600 Excellence in Project Mar + Regulatory Affairs + Phase | + Phase INA Proof of Concept + PK/PD/Pharmacometrics + Clinical Pharmacodynamics + Bioanalysis + CMC/Pre-Clinical + Biometrics + Medical Writing, Publishing * Quality Control, Assurance
Slide 98: Service Proposition
• Regulatory and Development Strategy • Protocol Design • Regulatory Submissions and Agency Meetings • Study/Program Execution • Evaluation and Reporting Ø From compound selection through development to approval and beyond Service Proposition
Slide 99: Scientific Capability
Area Collective Expertise Clinical Drug Development / Clinical Pharmacology >12 MDs/PhD >130 years experience, >1200 ph I/IIA trials Regulatory Affairs MSc/PhD >150 years EU/US experience CMC, Formulation Development >6 MSc/PhD >100 years experience PK/PD, Pharmacometrics MSc/PhD, over 100 years exp
Slide 100: Strategy For Growth
Area Activity Development Consulting Build on US strengths and expand in EU Regulatory, Publishing E-submission requirement in EU/US creates big growth opportunity Phase I US Phase I acquisition Expansion into special population studies PK, PD, Pharmacometrics Constant demand for services, modeling
Slide 101: ICON plc Global Organization
Chairman Dr. John Climax ICON Corporate Dev President Bill Taaffe CEO Peter Gray CFO Ciaran Murray ICON Development Solutions President Dr Thomas Frey Beacon Bioscience CEO Dr Ted Gastineau ICON Central Laboratories President Bob Scott-Edwards ICON Contracting Solutions Tony Southers Snr VP VP Corpo
Slide 102: Central Laboratory - 2006 Overview
Central Laboratory – 2006 Overview • Revenue grew by +65% ¯ Europe: +93%USA:+62% • Won 289 New studies ¯ Strike rate:47% ¯ Repeat business:88%(31 New Clients) • Backlog:~$100m(+26%) • Customer Satisfaction: ¯ 94% would use us again ¯ 94% would recommend us to colleagues ¯ 54% thought we were the “be
Slide 103: Central Laboratory - 2007 Outlook
Central Laboratory – 2007 Outlook • Target Revenue growth:>20% • Target margin:8-10% at year end • Expanding Sales Team • Organization growth tailored to demand • Expanded use of Six Sigma and Metrics • Continue to expand test menu/platforms ¯ Focus on Flow Cytometry and key biomarkers
Slide 104: Central Laboratory - 2007 Outlook
Central Laboratory – 2007 Outlook • Kit output: ¯ ~45,000 kits/month compared to ~25,000 in 2005 • Upgrading systems & processes to yield further efficiencies ¯ Kit automation initiative underway ¯ Upgrade to IT systems underway ¯ Launched new RDA system • Dublin has expanded – Laboratory & Support
Slide 105: Kits & Accessions - 2006
200,000 250,000 300,000 350,000 400,000 450,000 500,000 550,000 Jan-06 Feb-06 Mar-06 Apr-06 May-06 Jun-06 Jul-06 Aug-06 Sep-06 Oct-06 Nov-06 Dec-06 Total Kits Total Accessions Kits & Accessions - 2006
Slide 106: Challenges
Challenges… • Extending our Global presence… ¯ Singapore, India, China… ¯ Upgrading our Affiliate activity… • Adding high caliber staff • Retaining our distinctive style - ¯ A service business built around a Lab ¯ Producing high quality data ¯ Noted for Responsiveness and Flexibility ¯ Focused on Cu
Slide 107: ICON plc Global Organization
Chairman Dr. John Climax ICON Corporate Dev President Bill Taaffe CEO Peter Gray CFO Ciaran Murray ICON Development Solutions President Dr Thomas Frey Beacon Bioscience CEO Ted Gastineau ICON Central Laboratories President Bob Scott-Edwards ICON Contracting Solutions Tony Southers Snr VP VP Corporat
Slide 108: What we do
What we do Beacon provides a Complete Solution for medical imaging based product development.
Slide 109: A Complete Solution
A Complete Solution • Design Clinical Trial Design focused on imaging. Regulatory ________________________________________________________________ • Implement the imaging at hospitals _________________________________________________________________ • Manage all digital images centrally from radiolo
Slide 110: We think differently
We think differently • Imaging sees/measures structure and function • Each pixel represents a physiologic/metabolic characteristic. • Images are spatially distributed data
Slide 111: Information is a Verb
Information is a Verb “ Information: verb active information derived from passive data using a new level of information analysis.” -Michael Dertouzous, M.I.T. 1998
Slide 112: Therapeutic Growth (% Revenues)
2005 2006 Therapeutic Growth (%Revenues)
Slide 113: Medical Imaging 2005 and 2006 Global RFP Value
Medical Imaging – 2005 and 2006 Global RFP Value ($ Million)
Slide 114: Net Business Awards and Backlog
0600 -ASymbol of Excelence $30,000,000 $25,000,000 $20,000,000 $15,000,000 $10,000,000 $6,000,000 $0 2004 2005 2006 @Net Business Awarts @ Backlog
Slide 115: Revenue and EBITDA
-ASymbol of Excelence »LL 2004 2005 m Revenue 8 EBITDA, 2006
Slide 116: Re-branding Beacon Bioscience to ICON Medical Imaging
Re-branding Beacon Bioscience to ICON Medical Imaging • Beacon Bioscience will be re-branded to become ICON Medical Imaging • This reflects our further integration and our status as a core division of ICON • We are launching a year long campaign including mailers, meetings, and trade shows • Excelle
Slide 117: ICON plc Global Organization
Chairman Dr. John Climax ICON Corporate Dev President Bill Taaffe CEO Peter Gray CFO Ciaran Murray ICON Development Solutions President Dr Thomas Frey Beacon Bioscience CEO Ted Gastineau ICON Central Laboratories President Bob Scott-Edwards ICON Contracting Solutions Tony Southers Snr VP VP Corporat
Slide 118: BPA / MCS Acquisition October 2002
BPA / MCS Acquisition October 2002 • Two business segments BPA and MCS • BPA ¯ Clinical Division with good Transplant, Oncology and Vaccine experience ¯ BPA integrated into the US clinical division • MCS – ¯ Focused on contract staffing ¯ New service for ICON ¯ Stand alone status
Slide 119: BPA - Post Acquisition
BPA – Post Acquisition • BPA was integrated into ICON and many of the personnel are still with ICON 4 years on • Added to the overall value of ICON ¯ Critical mass when required and ¯ Therapeutic expertise and experience Success !!!!!!
Slide 120: June 2005
June 2005 • Tony Southers (Ex VP of BD-Europe) appointed Head of MCS ¯ Introduced a Sales Team and a Client ‘Service’ focus ¯ Improved / Updated processes & technology ¯ Upgraded candidate package ¯ Developed growth strategy ¯ Re-aligned the group into ICON and improved operational leverage ¯ Change
Slide 121: MCS Re-launch Plan
MCS Re-launch Plan ICS Revenue History
Slide 122: ICS Future Growth Opportunities
ICS Future Growth Opportunities • Growth within the US will continue ¯ 35% growth next year (current NY location) ¯ Expand permanent placement capabilities ¯ West Coast market exploration (build or buy) • Other opportunities within new markets ¯ Europe (build or buy) ¯ Advantage of offering global c
Slide 123: ICON PLC Q&A Session
ICON PLC Q&A Session